Alpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of “Hold” by Analysts
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) have been given a consensus rating of “Hold” by the five brokerages that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $10.83.
ALPN has been the topic of several recent analyst reports. Zacks Investment Research downgraded Alpine Immune Sciences from a “hold” rating to a “strong sell” rating in a report on Thursday, October 26th. ValuEngine upgraded Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th.
Shares of Alpine Immune Sciences (ALPN) traded up $0.14 during midday trading on Friday, hitting $11.35. The stock had a trading volume of 14,200 shares, compared to its average volume of 19,767. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.38 and a current ratio of 32.38. Alpine Immune Sciences has a 12-month low of $7.20 and a 12-month high of $14.52. The stock has a market capitalization of $157.56 and a P/E ratio of -1.31.
Alpine Immune Sciences Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.